NATCO Pharma liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
6.66×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.01×3.01×5.59×4.14×4.39×
2.47×2.47×4.77×3.42×3.30×
777777441514437
3,3713,3714,3273,0512,317
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCOPHARM₹787.55

NATCO Pharma Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,097 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————6.66
Current Ratio4.394.145.593.013.01
Quick Ratio3.303.424.772.472.47
Cash, Equiv & ST Investments436.9513.9440.8777.1777.1
Working Capital2,317.23,050.74,326.53,371.43,371.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.